Ruth A. Keri

This paper identifies collagen architecture and composition as prognostic biomarkers in triple-negative breast cancer, improving risk stratification beyond standard clinicopathologic features.

This study shows that SU056, a YB1 inhibitor, suppresses TNBC growth and metastasis by targeting the Rb pathway, with enhanced efficacy when combined with CDK4/6 inhibition.

The paper develops a novel mouse cell line model of invasive lobular breast carcinoma that recapitulates human tumor phenotype and immune microenvironment, offering a preclinical platform for therapy evaluation.

This study shows mitoxantrone inhibits ERα by binding at the DBD-LBD interface, causing conformational changes and degradation, and effectively targets ER mutations resistant to current therapies.

This paper identifies PML1 as a driver of endocrine resistance in ER+ breast cancer by forming a feedforward loop with PI3K and MAPK pathways, and shows that arsenic trioxide can disrupt this loop.

This study identifies disease mutations that perturb protein-protein interactions in the human 3D interactome, showing their association with cancer survival and drug response.